Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are comparing two different treatments for breast cancer that metastasized (spread) and makes high levels of the HER2 protein. The people in this study have metastatic HER2-positive breast cancer that keeps growing after trastuzumab deruxtecan (T-DXd). Or they may have had bad side effects from this drug and had to stop taking it.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
This study is assessing a new treatment approach for people with oligometastatic breast cancer. This means their cancer has spread to a small number of other parts of the body. Their cancers have high levels of the HER2 protein, which promotes breast cancer growth. In addition, they started drug therapy for their cancer and it has not gotten worse in the last 3-12 months.
The standard treatment for poor-risk and intermediate-risk germ cell tumors (GCTs), such as testicular cancer, is chemotherapy with the drugs bleomycin, etoposide, and cisplatin (abbreviated BEP) given every three weeks. In this study, researchers want to see if giving BEP chemotherapy every two weeks is more effective for controlling tumor growth than the standard regimen in patients with metastatic intermediate-risk and poor-risk GCTs.
Researchers are comparing RMC-6236 with standard therapy in people with advanced pancreatic cancer. The people in this study have pancreatic cancer that has metastasized (spread) and keeps growing even after treatment.
Researchers want to see how much the drug trastuzumab deruxtecan (T-DXd) can get into brain tumors. The people in this study have glioblastoma or cancer that spread to the brain from other parts of the body. They are scheduled to have brain tumor surgery. In addition, their tumors express (make) a protein called HER2, which boosts cancer cell growth. Researchers want to know if T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Researchers want to see if tumor-treating fields (TTFields) are safe and practical for people with lung adenocarcinoma before surgery. Lung adenocarcinoma is a type of lung cancer. If you join this study, you will get treatment with TTFields for up to 3 weeks before lung cancer surgery.
Researchers want to find the best dose of BMS-986458 to use alone and with rituximab to treat lymphoma. The people in this study have non-Hodgkin lymphoma (NHL) that came back or keeps growing after treatment.
In this study, researchers are assessing a new way to determine the best dosing of fludarabine. The people in this study are children and young adults getting CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). Their cancer has come back or keeps growing despite treatment. They will be getting a CAR T-cell therapy called tisagenlecleucel (Kymriah).
